Case Based Roundtable Logo

Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

Latest Articles

Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
November 26, 2024
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Timing of MRD Testing in Lung Cancer Affects Patient Outcomes
Timing of MRD Testing in Lung Cancer Affects Patient Outcomes
November 25, 2024
Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer
November 22, 2024
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Oncologists Experience Improved Survival in Patients With Melanoma
Oncologists Experience Improved Survival in Patients With Melanoma
November 21, 2024
Evan Lipson, MD, discusses feedback he’s received from colleagues about responses in patients with melanoma.
Target Switch and High-Risk Cohorts Support Talquetamab Use in RRMM
Target Switch and High-Risk Cohorts Support Talquetamab Use in RRMM
November 20, 2024
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants reacted to data from the MonumenTAL-1 trial in the first article of a 2-part series.
Antibody-Drug Conjugates Show Unique Advantage in Breast Cancer
Antibody-Drug Conjugates Show Unique Advantage in Breast Cancer
November 19, 2024
Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in sequence.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18, 2024
During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
November 15, 2024
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13, 2024
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Hematologists Should Consider What Comes Next for Patients With DLBCL
Hematologists Should Consider What Comes Next for Patients With DLBCL
November 12, 2024
Elizabeth A. Brem, MD, discusses the familiarity of treatments among oncologists for patients with diffuse large B-cell lymphoma in a Case-Based Roundtable event.
SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy
SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy
November 11, 2024
During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in differentiated thyroid cancer in the first article of a 2-part series.
Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy
Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy
November 08, 2024
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.
Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
November 06, 2024
During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ lung cancer in the first article of a 2-part series.
Ring Sideroblasts Status Affects Treatment Decisions for Frontline MDS
Ring Sideroblasts Status Affects Treatment Decisions for Frontline MDS
November 05, 2024
Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.
Patient Selection for Imetelstat Benefits From Considering AEs
Patient Selection for Imetelstat Benefits From Considering AEs
November 04, 2024
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.
View a specific disease type